资源描述
Ming Sound Tsao,MD,FRCPCDepartment of Pathology,Princess Margaret HospitalDivision of Cellular and Molecular Biology,Ontario Cancer InstituteUniversity of TorontoMolecular Pathology of Lung Cancer.Ming Sound Tsao,MD,FRCPCMole1ONTARIO CANCER INSTITUTE(OCI)PRINCESS MARGARET HOSPITAL.ONTARIO CANCER INSTITUTE(OCI)2Objective:lTo report the results of 2 important clinical trials reported at 2004 American Society of Clinical OncologistMain message:l Molecular Pathology will soon be an important component of pathological diagnosis in lung cancer.Objective:.3Worlds cancer incidence and cancer deathsIncidence in thousands(%total)Deaths in thousands(%total)Lung1,305(12.7%)1,211(17.2%)Colon&rectum1,045(10.2%)608(6.7%)Breast1,032(10%)430(6.1%)Stomach973(9.5%)835(11.9%)Liver626(6.1%)611(8.7%).Worlds cancer incidence and c41999 WHO Pathological Classification of Lung Cancer.1999 WHO Pathological Classifi5Non-small Cell Lung CancerAdenocarcinomaSquamous cell carcinoma.Non-small Cell Lung CancerAden6NSCLC-Survival Rate and Proportion at Presentation vs.Clinical stageClinical StagePercentage of Patients5-year survival rateI36%60%II8%39%IIIA10%23%IIIB20%5%IV27%2 regimens(9)Only single agent in young patient(2)CT or RT given within 2-4 weeks,concurrent CT(5)Biochemical abnormalities(4)Symptomatic CNS metastases(2).BR.21 Results731 patients rand36BR.21 Patient CharacteristicsErlotinib(N=488)Placebo(N=243)Median Age(yrs)62.259.5GenderMale65%66%Female35%34%ECOG PS(%)013%14%152%54%226%23%39%9%HistologyAdenocarcinoma50%49%Other50%51%.BR.21 Patient CharacteristicsE37BR.21 Progression Free Survival*Adjusted for stratification factors Months _ Erlotinib,_ Placebo *HR 0.61,p=0.001.BR.21 Progression Free Surviv38BR.21 Overall,Progression-Free and 1-year SurvivalErlotinib(N=488)Placebo(N=243)HR*Log Rank PProgression Free Survival2.2 m1.8 m0.61 0.001Overall Survival 6.7m4.7m0.720.001I-year survival31%22%*Adjusted for stratification factors.BR.21 Overall,Progression-Fr39BR.21 Overall Survival*Adjusted for stratification factors _ Erlotinib,_ Placebo *HR 0.72,p=0.001Months31%22%.BR.21 Overall Survival*Adjust40BR.21 Survival by Smoking HistoryMonths_ Erlotinib Non-Smoker_ Placebo Non-Smoker_ Erlotinib Smoker _ Placebo Smoker p=0.03*significant difference across the levels of the factor.BR.21 Survival by Smoking Hist41BR.21 SummaryThis is the first placebo controlled randomized trial to confirm that an oral tyrosine（酪氨酸）kinase inhibitor of EGFR can prolong survivalTreatment with erlotinib was associated with significantlyllonger overall survivalllonger progression free survivallimproved lung cancer-related symptomslimproved quality of lifeSurvival significantly better among non-smokers.BR.21 SummaryThis is the first42EGFR Mutations in Lung Cancer:Correlation with Clinical Response to Gefitinib Therapy.Paez JG,Janne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H,Fujii Y,Eck MJ,Sellers WR,Johnson BE,Meyerson M.Dana Farber Cancer Institute and Harvard UniversityScience April 29,2004 Mutations（突变）(point mutation and deletions)were detected in exons（外显子）18,19 and 21 in the kinase domain of EGFR gene.Mutations were found in:l26%(15/68)of lung cancers from Japanl 2%(1/61)of lung cancers from USA Mutations among Japanese patients:l14/15 were in adenocarcinomal8/14(57%)women with adenocarcinoma had mutations Mutations were found in:l all 5 patients who responded to gefitinib(Iressa)treatment at DFCIl none of 4 patients who did not respond to gefitinib treatment.Mutations（突变）(point mutation43Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non Small-Cell Lung Cancer to GefitinibThomas J.Lynch,M.D.,Daphne W.Bell,Ph.D.,Raffaella Sordella,Ph.D.,Sarada Gurubhagavatula,M.D.,Ross A.Okimoto,B.S.,Brian W.Brannigan,B.A.,Patricia L.Harris,M.S.,Sara M.Haserlat,B.A.,Jeffrey G.Supko,Ph.D.,Frank G.Haluska,M.D.,Ph.D.,David N.Louis,M.D.,David C.Christiani,M.D.,Jeff Settleman,Ph.D.,and Daniel A.Haber,M.D.,Ph.D.Massachusetts General Hospital and Harvard Medical SchoolNEW ENGLAND JOURNAL OF MEDICINE,MAY 20 ISSUE EGFR mutations were found in:8 of 9 lung cancer patients who were responsive to treatment with Iressa 0 of 7 lung cancer patients who were non-responsive All 8 tumors were adenocarcioma 5 of 8 were from women non-smokers Mutations were not found in 95 non-lung cancer tumors.Activating Mutations in the Ep44.45International Association for the Study of Lung Cancer EGFR Summit Meeting HighlightsJuly 9-10,2004,Baltimore,USA There are 18 mutations that have been described in exons 18-23.Rates of mutations varied according to countries:lAdenocarcinoma in never smokers:60%in tumors from Taiwan 62%from Japan 30 45%from USA(compared to 2%overall)80%from Hong Kongl Adenocarcinoma of ever smoker from HK:40%EGFR mutation and Ras mutations are mutually（相互）exclusive排斥 In Korea where women rarely smoke,response to Iressa is seen in up to 60%of patients.International Association for 46Future studies What are the best predictors of benefits in patients treated with EGFR TKI?l Mutation alone?l Other gene or protein markers in the tumor or serum.Future studies What are the be47Future improvement in lung cancer diagnosis and treatment will be based on better understanding of the molecular pathology of lung cancer.Molecular diagnosis will play increasingly important roles in future management of lung cancer patients.Final Comments.Future improvement in lung can48AcknowledgementLaboratory personnel:l Liu Ni l Zhu Chang-Qil Davina LauPast visiting fellows:l Fiona Blackhall(Manchester)l Mu Xiao-yan(Shandong)l Lu Ming(Beijing)Dr.Frances Shepherd(Medical oncologist and current President of IASLC)Thoracic surgeons at Toronto General Hospital/Princess Margaret Hospital National Cancer Institute of Canada Clinical Trial Group and staffs.AcknowledgementLaboratory pers49感谢亲观看此幻灯片，此课件部分内容来源于网络，感谢亲观看此幻灯片，此课件部分内容来源于网络，如有侵权请及时联系我们删除，谢谢配合！如有侵权请及时联系我们删除，谢谢配合！感谢亲观看此幻灯片，此课件部分内容来源于网络，50
展开阅读全文